Entering text into the input field will update the search result below

FDA OKs Merck treatment for babies with HIV

Jan. 08, 2014 9:51 AM ETMerck & Co., Inc. (MRK) StockMRKBy: Yigal Grayeff, SA News Editor
  • The FDA has approved Merck's (MRK -0.9%) Isentress oral formulation for treating HIV-1 infection in babies who are four weeks old and above when used with other therapies, which appears to increase the chances of success.
  • Merck expects the formulation to be available in the U.S. in Q3. (PR)

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.